Silence Therapeutics has launched legal action alleging that late stage drugs from rivals Alnylam and The Medicines Company infringe its intellectual property. Silence, which specialises in ...

Alnylam markets it as Amvuttra. Like Alnylam’s other approved drugs, it relies on RNA interference, or RNAi, a Nobel Prize-winning approach to silence disease-causing genes. And, like the other ...

Alnylam’s pipeline is built on small interfering RNA (siRNA), synthetic molecules that silence specific mRNAs. After nearly 15 years of investment in the field, Alnylam is now nearing the moment ...

Alnylam Pharmaceuticals has shared positive new results from a late-stage trial of its RNAi therapeutic Amvuttra (vutrisiran) in transthyretin amyloid cardiomyopathy (ATTR-CM), an under-diagnosed and ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) on Saturday released additional data from its Phase 3 HELIOS-B trial, which evaluated its recently approved RNAi therapy Amvuttra (vutrisiran) in patients ...

An in-depth analysis of recent analyst actions unveils how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based ...